Literature DB >> 27840905

Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells.

Mohd Firdaus Che Mat1, Nor Azian Abdul Murad1, Kamariah Ibrahim1, Norfilza Mohd Mokhtar1, Wan Zurinah Wan Ngah1, Roslan Harun1, Rahman Jamal1.   

Abstract

Glioblastoma multiforme (GBM) is an aggressive brain tumor and most patients have poor prognosis. Despite many advances in research, there has been no significant improvement in the patient survival rate. New molecular therapies are being studied and RNA interference (RNAi) therapy is one of the promising approaches to improve prognosis and increase survival in patients with GBM. We performed a meta‑analysis of five different microarray datasets and identified 460 significantly upregulated genes in GBM. Loss‑of‑function screening of these upregulated genes using LN18 cells was performed to identify the significant target genes for glioma. Further investigations were performed using siRNA in LN18 cells and various functional assays were carried out on the selected candidate gene to understand further its role in GBM. We identified PROS1 as a candidate gene for GBM from the meta‑analysis and RNAi screening. Knockdown of PROS1 in LN18 cells significantly induced apoptosis compared to siPROS1‑untreated cells (p<0.05). Migration in cells treated with siPROS1 was reduced significantly (p<0.05) and this was confirmed with wound-healing assay. PROS1 knockdown showed substantial reduction in cell invasion up to 82% (p<0.01). In addition, inhibition of PROS1 leads to decrease in cellular proliferation by 18%. Knockdown of PROS1 in LN18 cells caused activation of both of the extrinsic and intrinsic apoptotic pathways. It caused major upregulation of FasL which is important for death receptor signaling activation and also downregulation of GAS6 and other members of TAM family of receptors. PROS1 may play an important role in the development of GBM through cellular proliferation, migration and invasion as well as apoptosis. Targeting PROS1 in GBM could be a novel therapeutic strategy in GBM treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27840905     DOI: 10.3892/ijo.2016.3755

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

Review 1.  The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.

Authors:  Bridget Shafit-Zagardo; Ross C Gruber; Juwen C DuBois
Journal:  Pharmacol Ther       Date:  2018-03-04       Impact factor: 12.310

Review 2.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

3.  Aberrant expression of PROS1 correlates with human papillary thyroid cancer progression.

Authors:  Jing Wang; Minxiang Lei; Zhijie Xu
Journal:  PeerJ       Date:  2021-08-03       Impact factor: 2.984

Review 4.  TAM receptors, Phosphatidylserine, inflammation, and Cancer.

Authors:  Tal Burstyn-Cohen; Avi Maimon
Journal:  Cell Commun Signal       Date:  2019-11-27       Impact factor: 5.712

Review 5.  Immuno-oncology: are TAM receptors in glioblastoma friends or foes?

Authors:  Yunxiang Zhou; Yali Wang; Hailong Chen; Yanyan Xu; Yi Luo; Yongchuan Deng; Jianmin Zhang; Anwen Shao
Journal:  Cell Commun Signal       Date:  2021-01-28       Impact factor: 5.712

Review 6.  Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment.

Authors:  Jane Koo; Masanori Hayashi; Michael R Verneris; Alisa B Lee-Sherick
Journal:  Front Oncol       Date:  2020-12-14       Impact factor: 6.244

7.  LncRNA RP3-525N10.2-NFKB1-PROS1 triplet-mediated low PROS1 expression is an onco-immunological biomarker in low-grade gliomas: a pan-cancer analysis with experimental verification.

Authors:  Yujie Zhou; Dongdong Xiao; Xiaobing Jiang
Journal:  J Transl Med       Date:  2022-07-25       Impact factor: 8.440

8.  The TAM family as a therapeutic target in combination with radiation therapy.

Authors:  Garth W Tormoen; Marka R Crittenden; Michael J Gough
Journal:  Emerg Top Life Sci       Date:  2017-12-12

9.  CeRNA regulatory network-based analysis to study the roles of noncoding RNAs in the pathogenesis of intrahepatic cholangiocellular carcinoma.

Authors:  Weiyu Xu; Si Yu; Jianping Xiong; Junyu Long; Yongchang Zheng; Xinting Sang
Journal:  Aging (Albany NY)       Date:  2020-01-17       Impact factor: 5.682

10.  Proteomics changes after negative pressure wound therapy in diabetic foot ulcers.

Authors:  Zeguo Jia; Lei Liu; Shiqian Zhang; Xiaotong Zhao; Li Luo; Yizhong Tang; Bing Shen; Mingwei Chen
Journal:  Mol Med Rep       Date:  2021-10-05       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.